Publications

Publications from the last five years

Lee, H.-F., Lacbay, C.M., Boutin, R., Matralis, A.N., Park, J., Waller, D.D., Guan, T.L., Sebag, M., & Tsantrizos, Y.S. Synthesis and evaluation of structurally diverse C-2-substituted thienopyrimidine-based inhibitors of the human geranylgernayl pyrophosphate synthase. J Med Chem. 2022 Jan 25; 65(3):2417–2496.

Bassenden, A.V., Dumalo, L., Park, J., Blanchet, J., Maiti, K., Arya, D.P., & Berghuis, A.M. Structural and phylogenetic analyses of resistance to next-generation aminoglycosides conferred by AAC(2') enzymes. Sci Rep. 2021 Jun 2; 11:11614.

Zielinski, M., Park, J., Sleno, B., & Berghuis, A.M. Structural and functional insights into esterase-mediated macrolide resistance. Nat Commun. 2021 Mar 19; 12:1732.

Park, J., Pandya, V.R., Ezekiel, S.J., & Berghuis, A.M. Phosphonate and bisphosphonate inhibitors of farnesyl pyrophosphate synthases: a structure-guided perspective. Front Chem. 2021 Jan 6; 8:612728.

Ilie, A., Boucher, A., Park, J., Berghuis, A.M., McKinney, R.A., & Orlowski, J. Assorted dysfunction of endosomal alkali cation/proton exchanger SLC9A6 variants linked to Christianson syndrome. J Biol Chem. 2020 May 15; 295(20):7075–7095.

Bassenden, A., Park, J., Rodionov, D., & Berghuis, A.M. Revisiting the catalytic cycle and kinetic mechanism of ANT (2”): a structural and kinetic study. ACS Chemical Biology. 2020 Feb 26; 15(3):686–694.

Feng, Y., Park, J., Li, S.G., Boutin, R., Viereck, P., Schilling, M.A., Berghuis, A.M., & Tsantrizos, Y.S. Chirality-driven mode of binding of a-aminophosphonic acid-based allosteric inhibitors of the human farnesyl pyrophosphate synthase (hFPPS). J Med Chem. 2019 Nov 14; 62(21):9691–9702.

Gobeil, S.M.C., Ebert, M.C.C. J.C., Park, J., Gagne, D., Doucet, N., Berghuis, A.M., Pleiss, J. & Pelletier, J.N. The structural dynamics of engineered β-lactamases vary broadly on three timescales yet sustain native function. Sci Rep. 2019 Apr 30; 9(1):6656.

Waller, D.D., Park, J., & Tsantrizos, Y.S. Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers. Crit Rev Biochem Mol Biol. 2019 Feb; 54(1):41–60.

Ilie, A., Gao, A.Y.L., Boucher, A., Park, J., Berghuis, A.M., Hoffer, M.J.V., Hilhorst-Hofstee, Y., McKinney, R.A., & Orlowski, J. A potential gain-of-function variant of SLC9A6 leads to endosomal alkalinization and neuronal atrophy associated with Christianson Syndrome. Neurobiol Dis. 2019 Jan; 121:187–204.

Lacbay, C.M., Waller, D.D., Park, J., Gomez Palou, M., Vincent, F., Huang, X.F., Ta, V., Berghuis, A.M., Sebag, M., & Tsantriozs, Y.S. Unraveling the prenylation-cancer paradox in multiple myeloma with novel geranylgeranyl pyrophosphate synthase (GGPPS) inhibitors. J Med Chem. 2018 Aug 9; 61(15):6904–6917.

Park, J., Rodionov, D., De Schutter, J.W., Lin, Y.S., Tsantrizos, Y.S., & Berghuis, A.M. Crystallographic and thermodynamic characterization of binding of phenylaminopyridine bisphosphonates to human farnesyl pyrophosphate synthase. PLoS One. 2017 Oct 16; 12(10):e0186447.

Park, J., Leung, C.Y., Matralis, A.N., Lacbay, C.M., Tsakos, M., Fernandez De Troconiz, G., Berghuis, A.M., & Tsantrizos, Y.S. Pharmacophore mapping of thienopyrimidine-based monophosphonate (ThP-MP) inhibitors of the human farnesyl pyrophosphate synthase. J Med Chem. 2017 Mar 9; 60(5):2119–2134.

Park, J., Zielinski, M., Magder, A., Tsantrizos, Y.S., & Berghuis, A.M. Human farnesyl pyrophosphate synthase is allosterically regulated by its own product. Nat Commun. 2017 Jan 18; 8:14132.